An executive of the new hospital-owned drug company Civica Rx said he and his partners are pleased with the response they've received from Capitol Hill regulators since announcing the formation of their nonprofit this fall, but they're fine navigating things on their own.
"Basically, the responses were, 'What can we do to help you?'" Dan Liljenquist, senior vice president and chief strategy officer of Salt Lake City-based Intermountain Healthcare told STAT.
The collaboration of seven major health system will begin by manufacturing 14 hospital-administered generic drugs that have been in short supply.
Interest from those regulators mirrors the Trump administration's focus on bringing down drug prices and improving drug shortages.
But after meeting with the regulators, Mr. Liljenquist said the company doesn't have much to ask for from the FDA or Capitol Hill.
"We said, look: Just apply the same rules you apply to everybody else to us, and that’s all we need," Mr. Liljenquist told STAT. "We are not looking to Washington to solve this issue."
Read the full report here.